Here, we explain the facts behind several more of Robert F. Kennedy Jr.’s claims during his two Senate hearings as nominee ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Discover how modern diabetes medications offer cardiovascular benefits, transforming diabetes care and improving outcomes worldwide.

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...

DexCom (NASDAQ: DXCM) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track ...

Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Certain diabetes medications may have additional health benefits for older adults, scientists from the University of Glasgow ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...